AstraZeneca Signs Cambridge-Based Cancer Research Deals

AstraZeneca Plc is pursuing three research projects with the University of Cambridge and Cancer Research UK to try to identify changes in tumor cells and test combinations of its drugs to better treat some cancer patients.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.